News

Fibrocell received $1.4 million from the U.S. Food and Drug Administration’s Office of Orphan Products Development (OOPD) to support the company’s ongoing clinical trials testing its FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In collaboration with Precigen (a wholly owned subsidiary of…

More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…

Despite broken bones and all manner of inclement weather, Robb Freed is seven months and 7,000 miles into his super-human quest to bike across the United States and back to raise awareness of epidermolysis bullosa (EB). His 13-month-old son died from the disease 10 years ago. Freed’s on the…

A family of enzymes with genome-editing function to enhance immune system responses are driving the high rate of skin cancer in patients with recessive dystrophic epidermolysis bullosa (RDEB), a new study shows. The study also reports that the type of mutations present in RDEB skin tumors are closer to…

U.S. residents with some types of inherited epidermolysis bullosa (EB) can now participate in Amryt Pharma‘s Phase 3 trial testing AP101 (Oleogel-S10), an experimental treatment for EB. This comes in the wake of the U.S. Food and Drug Administration granting investigational new drug (IND) clearance to AP101. The…

A recent study using technology that powers NantOmics‘ comprehensive GPS Cancer test confirmed that chronic inflammation caused by the inherited childhood skin disease recessive dystrophic epidermolysis bullosa (RDEB) can lead to a rare form of skin cancer known as squamous cell carcinoma (SCC). The study, “APOBEC mutation…

New York-based EB Research Partnership (EBRP), along with the EB Research Foundation in Australia, announced a global collaboration that aims to develop lifesaving treatments for patients with epidermolysis bullosa (EB). Under the rules of the partnership, the EB Research Foundation will help fund the EBRP’s independent Scientific Advisory Board (SAB).

Treatment with a wound care ointment called Terrasil reduced pain, itching, and blistering in the wound area in a patient with a long history of junctional epidermolysis bullosa (JEB), according to a new case report. The study, “Epidermolysis bullosa: a case report,” published in the…

Lena Riedl, 24, has had epidermolysis bullosa (EB) since birth. Despite the suffering, she’s managed to turn her genetic “butterfly disease” into a career while inspiring her father, Rainer Riedl, to launch the world’s first dedicated EB clinic in her native Austria. The cheerful young woman is a communications and…

Castle Creek Pharmaceuticals‘ investigational treatment CCP-020 (diacerein 1% ointment) was granted Fast Track designation by the U.S. Food and Drug Administration to treat a type of epidermolysis bullosa (EB) called EB simplex (EBS). Castle Creek is investigating CCP-020 to treat EBS patients in an ongoing Phase 2 trial…

RGN-137, an experimental therapy for wound healing in epidermolysis bullosa (EB), is expected to advance into a Phase 3 trial, backed by a joint venture created by RegeneRx licensee GtreeBNT and YuYang DNU…

Amryt Pharma’s investigational therapy AP101, designed to reduce the time it takes for skin wounds to close, was granted Rare Pediatric Disease designation by the U.S. Food and Drug Administration for the treatment of children with epidermolysis bullosa (EB). Rare Pediatric Disease status is granted to…